CGEM · CIK 0001789972
What Cullinan Therapeutics, Inc. told the SEC could break it.
Cullinan is a pre-commercial biopharma whose disclosures concentrate on two dependencies. On supply, it relies on third parties in China to manufacture certain raw materials, drug substances, and drug products, and its global CMO network has single-source nodes — so a China disruption, trade war, or CMO halt could stall its development programs. On value and funding, its most material near-term driver is the Taiho collaboration on zipalertinib: up to $130 million in milestones tied to U.S. EGFR ex20ins lung-cancer approvals plus 50% of any future U.S. profits, all of which evaporates if zipalertinib fails. With no product revenue and operations funded by equity and licensing ($377.9 million cash at year-end 2025), it remains dependent on future financing and on FDA approval and reimbursement amid IRA Medicare drug-pricing reform.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- China-based CMOs for raw materials/drug substance; single-source nodes in global supply chainhigh
Cullinan relies on third parties in China to manufacture and supply certain raw materials, drug substances and drug products, and its global CMO network has single-source nodes in the drug-substance/product supply chains; a China disruption, trade war or CMO halt could stall its development programs.
“for some of our product candidates, we rely on third parties located in China to manufacture and supply certain raw materials, drug substances, and/or drug products, and we expect to continue to use such third-party manufacturers as needed.”
Liquidity & debt
- no product revenue; reliant on equity/licensing financingmedium
Cullinan has never generated product-sales revenue and has funded operations through equity sales and licensing/asset sales (net $842.2M equity, $275.0M from the Taiho subsidiary sale); although it held $377.9M cash at year-end 2025, continued clinical spend keeps it dependent on future financing.
“We have not generated any revenue from the sale of products since our inception.”
SEC filing →As of 2026
Other disclosures
- non-dilutive funding dependent on Taiho zipalertinib milestones and profit sharemedium
Cullinan's most material near-term value driver depends on its Taiho collaboration — up to $130M in milestone payments tied to U.S. EGFR ex20ins NSCLC approvals plus 50% of any future U.S. zipalertinib profits — so clinical/regulatory failure of zipalertinib or Taiho's commercialization would remove that non-dilutive funding.
“Cullinan is also eligible to receive up to a $100.0 million payment from Taiho upon U.S. regulatory approval of zipalertinib for the first-line treatment for adult patients with locally advanced or metastatic EGFR ex20ins NSCLC. We and Taiho will each receive 50% of any future pre-tax profits from potential U.S. sales of zipalertinib.”
SEC filing →As of 2026
Regulatory & policy
- FDA approval dependence; IRA Medicare drug-pricing and healthcare reformmedium
As a pre-commercial biopharma, Cullinan depends on FDA/foreign approvals and future reimbursement; the Inflation Reduction Act's Medicare Part B/D drug-price provisions, elimination of the Medicaid rebate cap, and biosimilar competition under the ACA could pressure the pricing and reimbursement of any approved products.
“the Inflation Reduction Act of 2022 (the “IRA”) includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes, which have varying implementation dates, include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price i”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Taiho Pharmaceutical Co., Ltd.
“Under an agreement with Taiho, we are eligible to receive $30.0 million and up to $100.0 million in payments from Taiho tied to United States (“U.S.”) regulatory approvals in second-line and first-line EGFR ex20ins NSCLC, respectively. We are also eligible to receive 50% of any future pre-tax profits from potential U.S. sales of zipalertinib.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch